Carisma: Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Carisma Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 9.27 million compared to USD 18.98 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.22 compared to USD 0.46 a year ago. Carisma Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 9.27 million compared to USD 18.98 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.22 compared to USD 0.46 a year ago.